LB-4. Cefepime-Enmetazobactam Demonstrates Superiority to Piperacillin-Tazobactam in a Subgroup of Patients with Complicated Urinary Tract Infections/Acute Pyelonephritis Caused by Extended Spectrum β-Lactamase-Producing Enterobacterales

BACKGROUND: There is a critical need for carbapenem-sparing therapies for infections caused by extended spectrum β-lactamase (ESBL)-producing Enterobacterales. Enmetazobactam is a novel ESBL inhibitor combined with the cephalosporin cefepime. Treatment outcomes of cefepime-enmetazobactam (FPE) versu...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Open Forum Infect Dis
Hlavní autoři: Belley, Adam, Barth, Philip, Kashyap, Shikhar, Lahlou, Omar, Motta, Paola, Knechtle, Philipp, Velicitat, Patrick
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2020
Témata:
Late Breaker Abstracts
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7776372/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa515.1901
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky